Ketamine as the anaesthetic for electroconvulsive therapy

the KANECT randomised controlled trial

Gordon Fernie (Corresponding Author), James Currie, Jennifer S. Perrin, Caroline A. Stewart, Virginica Anderson, Daniel M. Bennett, Steven Hay, Ian C. Reid

Research output: Contribution to journalArticle

15 Citations (Scopus)
6 Downloads (Pure)

Abstract

Background

Ketamine has recently become an agent of interest as an acute treatment for severe depression and as the anaesthetic for electroconvulsive therapy (ECT). Subanaesthetic doses result in an acute reduction in depression severity while evidence is equivocal for this antidepressant effect with anaesthetic or adjuvant doses. Recent systematic reviews call for high-quality evidence from further randomised controlled trials (RCTs).

Aims

To establish if ketamine as the anaesthetic for ECT results in fewer ECT treatments, improvements in depression severity ratings and less memory impairment than the standard anaesthetic.

Method

Double-blind, parallel-design, RCT of intravenous ketamine (up to 2 mg/kg) with an active comparator, intravenous propofol (up to 2.5 mg/kg), as the anaesthetic for ECT in patients receiving ECT for major depression on an informal basis. (Trial registration: European Clinical Trials Database (EudraCT): 2011-000396-14 and clinicalTrials.gov: NCT01306760.)

Results

No significant differences were found on any outcome measure during, at the end of or 1 month following the ECT course.

Conclusions

Ketamine as an anaesthetic does not enhance the efficacy of ECT.
Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalBritish Journal of Psychiatry
Volume210
Issue number3
Early online date2 Mar 2017
DOIs
Publication statusPublished - Mar 2017

Fingerprint

Electroconvulsive Therapy
Ketamine
Anesthetics
Randomized Controlled Trials
Depression
Anesthesia Adjuvants
Propofol
Antidepressive Agents
Outcome Assessment (Health Care)
Clinical Trials
Databases
Therapeutics

Cite this

Ketamine as the anaesthetic for electroconvulsive therapy : the KANECT randomised controlled trial. / Fernie, Gordon (Corresponding Author); Currie, James; Perrin, Jennifer S.; Stewart, Caroline A. ; Anderson, Virginica; Bennett, Daniel M.; Hay, Steven; Reid, Ian C.

In: British Journal of Psychiatry, Vol. 210, No. 3, 03.2017, p. 1-7.

Research output: Contribution to journalArticle

Fernie, Gordon ; Currie, James ; Perrin, Jennifer S. ; Stewart, Caroline A. ; Anderson, Virginica ; Bennett, Daniel M. ; Hay, Steven ; Reid, Ian C. / Ketamine as the anaesthetic for electroconvulsive therapy : the KANECT randomised controlled trial. In: British Journal of Psychiatry. 2017 ; Vol. 210, No. 3. pp. 1-7.
@article{1402da20346449678e43db463a57afd2,
title = "Ketamine as the anaesthetic for electroconvulsive therapy: the KANECT randomised controlled trial",
abstract = "BackgroundKetamine has recently become an agent of interest as an acute treatment for severe depression and as the anaesthetic for electroconvulsive therapy (ECT). Subanaesthetic doses result in an acute reduction in depression severity while evidence is equivocal for this antidepressant effect with anaesthetic or adjuvant doses. Recent systematic reviews call for high-quality evidence from further randomised controlled trials (RCTs).AimsTo establish if ketamine as the anaesthetic for ECT results in fewer ECT treatments, improvements in depression severity ratings and less memory impairment than the standard anaesthetic.MethodDouble-blind, parallel-design, RCT of intravenous ketamine (up to 2 mg/kg) with an active comparator, intravenous propofol (up to 2.5 mg/kg), as the anaesthetic for ECT in patients receiving ECT for major depression on an informal basis. (Trial registration: European Clinical Trials Database (EudraCT): 2011-000396-14 and clinicalTrials.gov: NCT01306760.)ResultsNo significant differences were found on any outcome measure during, at the end of or 1 month following the ECT course.ConclusionsKetamine as an anaesthetic does not enhance the efficacy of ECT.",
author = "Gordon Fernie and James Currie and Perrin, {Jennifer S.} and Stewart, {Caroline A.} and Virginica Anderson and Bennett, {Daniel M.} and Steven Hay and Reid, {Ian C.}",
note = "C.AS. reports grants from Vifor Pharma, outside the submitted work. I.C.R. (deceased) declared personal fees from AstraZeneca, Sanofi Aventis and Sunovion, and non-financial support from Lundbeck, between 2009 and 2014 and all outside the submitted work. Volume 212, Issue 5 May 2018 , p. 323 Ketamine as the anaesthetic for electroconvulsive therapy: the KANECT randomised controlled trial – CORRIGENDUM Gordon Fernie, James Currie, Jennifer S. Perrin, Caroline A. Stewart... https://doi.org/10.1192/bjp.2018.76 Published online: 06 April 2018 Summary: This notice describes a correction to the above mentioned paper.",
year = "2017",
month = "3",
doi = "10.1192/bjp.bp.116.189134",
language = "English",
volume = "210",
pages = "1--7",
journal = "British Journal of Psychiatry",
issn = "0007-1250",
publisher = "Royal College of Psychiatrists",
number = "3",

}

TY - JOUR

T1 - Ketamine as the anaesthetic for electroconvulsive therapy

T2 - the KANECT randomised controlled trial

AU - Fernie, Gordon

AU - Currie, James

AU - Perrin, Jennifer S.

AU - Stewart, Caroline A.

AU - Anderson, Virginica

AU - Bennett, Daniel M.

AU - Hay, Steven

AU - Reid, Ian C.

N1 - C.AS. reports grants from Vifor Pharma, outside the submitted work. I.C.R. (deceased) declared personal fees from AstraZeneca, Sanofi Aventis and Sunovion, and non-financial support from Lundbeck, between 2009 and 2014 and all outside the submitted work. Volume 212, Issue 5 May 2018 , p. 323 Ketamine as the anaesthetic for electroconvulsive therapy: the KANECT randomised controlled trial – CORRIGENDUM Gordon Fernie, James Currie, Jennifer S. Perrin, Caroline A. Stewart... https://doi.org/10.1192/bjp.2018.76 Published online: 06 April 2018 Summary: This notice describes a correction to the above mentioned paper.

PY - 2017/3

Y1 - 2017/3

N2 - BackgroundKetamine has recently become an agent of interest as an acute treatment for severe depression and as the anaesthetic for electroconvulsive therapy (ECT). Subanaesthetic doses result in an acute reduction in depression severity while evidence is equivocal for this antidepressant effect with anaesthetic or adjuvant doses. Recent systematic reviews call for high-quality evidence from further randomised controlled trials (RCTs).AimsTo establish if ketamine as the anaesthetic for ECT results in fewer ECT treatments, improvements in depression severity ratings and less memory impairment than the standard anaesthetic.MethodDouble-blind, parallel-design, RCT of intravenous ketamine (up to 2 mg/kg) with an active comparator, intravenous propofol (up to 2.5 mg/kg), as the anaesthetic for ECT in patients receiving ECT for major depression on an informal basis. (Trial registration: European Clinical Trials Database (EudraCT): 2011-000396-14 and clinicalTrials.gov: NCT01306760.)ResultsNo significant differences were found on any outcome measure during, at the end of or 1 month following the ECT course.ConclusionsKetamine as an anaesthetic does not enhance the efficacy of ECT.

AB - BackgroundKetamine has recently become an agent of interest as an acute treatment for severe depression and as the anaesthetic for electroconvulsive therapy (ECT). Subanaesthetic doses result in an acute reduction in depression severity while evidence is equivocal for this antidepressant effect with anaesthetic or adjuvant doses. Recent systematic reviews call for high-quality evidence from further randomised controlled trials (RCTs).AimsTo establish if ketamine as the anaesthetic for ECT results in fewer ECT treatments, improvements in depression severity ratings and less memory impairment than the standard anaesthetic.MethodDouble-blind, parallel-design, RCT of intravenous ketamine (up to 2 mg/kg) with an active comparator, intravenous propofol (up to 2.5 mg/kg), as the anaesthetic for ECT in patients receiving ECT for major depression on an informal basis. (Trial registration: European Clinical Trials Database (EudraCT): 2011-000396-14 and clinicalTrials.gov: NCT01306760.)ResultsNo significant differences were found on any outcome measure during, at the end of or 1 month following the ECT course.ConclusionsKetamine as an anaesthetic does not enhance the efficacy of ECT.

UR - http://10.1192/bjp.2018.76

U2 - 10.1192/bjp.bp.116.189134

DO - 10.1192/bjp.bp.116.189134

M3 - Article

VL - 210

SP - 1

EP - 7

JO - British Journal of Psychiatry

JF - British Journal of Psychiatry

SN - 0007-1250

IS - 3

ER -